Get the Stockscreener App
6.36
1.24%
-0.08
After Hours:
6.36
Capricor Therapeutics Inc stock is traded at $6.36, with a volume of 636.37K.
It is down -1.24% in the last 24 hours and down -20.90% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$6.44
Open:
$6.47
24h Volume:
636.37K
Relative Volume:
0.27
Market Cap:
$290.76M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-7.6627
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-5.64%
1M Performance:
-20.90%
6M Performance:
-51.34%
1Y Performance:
+52.15%
1-Day Range:
$6.27
$6.47
1-Week Range:
$6.045
$6.77
52-Week Range:
$4.20
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.36 | 289.39M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - WV News
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, - GlobeNewswire
CAPR DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 15 Deadline in Securities Class Action – CAPR - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - Barchart.com
CAPRICOR DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
Capricor Therapeutics Files $300 Million Mixed Shelf - MarketScreener
Capricor Therapeutics files for mixed shelf offering of up to $300 million- SEC filing - MarketScreener
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Securities Fraud Class Action Filed Against Capricor Therapeutics, Inc. (CAPR)Levi & Korsinsky Reminds Investors of September 15, 2025 - Barchart.com
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc. - GlobeNewswire
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - Newsfile
Capricor refutes FDA’s DMD deramiocel rejection in public statement - Yahoo Finance
CAPR DEADLINE NOTICE: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
Investors SueWallSt Over Capricor Therapeutics, Inc. Stock DropContact Levi & Korsinsky to Join - ACCESS Newswire
Capricor Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Barchart.com
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet - simplywall.st
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - Business Wire
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel - GlobeNewswire
CAPR INVESTOR ALERT: Kirby McInerney LLP Notifies Capricor Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit - Business Wire
Levi & Korsinsky Invites Investors to SueWallSt After Capricor Therapeutics, Inc. Stock Collapse - ACCESS Newswire
Shareholders of Capricor Therapeutics, Inc. Should Contact - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) largest shareholders are retail investors with 58% ownership, institutions own 30% - Yahoo Finance
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class ActionCAPR - Morningstar
New SueWallSt Podcast Episode: Levi & Korsinsky Breaks Down Capricor Therapeutics, Inc. Case - Louisiana First News
Nuveen LLC Purchases New Shares in Capricor Therapeutics, Inc. $CAPR - MarketBeat
AWM Investment Company Inc. Takes Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
5 Companies Caught on a Carousel of FDA Confusion - BioSpace
CAPR FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important September 15 Deadline in Securities Class ActionCAPR - ACCESS Newswire
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Class Action Lawsuit Filed: Capricor Therapeutics, Inc. (CAPR)Join by September 15, 2025Contact Levi & Korsinsky - Stockhouse
Faruqi & Faruqi Reminds Capricor Investors of the Pending - GlobeNewswire
User - FinancialContent
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - The Malaysian Reserve
Can Capricor Therapeutics Inc. stock double in the next yearJuly 2025 Spike Watch & Comprehensive Market Scan Insights - خودرو بانک
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
CAPR FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, - GlobeNewswire
Silicon Valley - FinancialContent
Short interest data insights for Capricor Therapeutics Inc.Quarterly Portfolio Review & Weekly Hot Stock Watchlists - Newser
Join Class Action to Recover Losses from Capricor Therapeutics, Inc. (CAPR)Contact Levi & Korsinsky Before September 15, 2025 - Barchart.com
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Morningstar
The Gross Law Firm Reminds Capricor Investors of the - GlobeNewswire
CAPR LAWSUIT ALERT: The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):